Current and up-and-coming pharmacotherapy for obsessive-compulsive disorder in adults
- 22 September 2018
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 19 (14) , 1541-1550
Abstract
Introduction: Only 40–60% of obsessive-compulsive patients respond to first line treatments, such as selective serotonin reuptake inhibitors (SSRIs) and cognitive-behavioral therapy. Several second-line treatments have been investigated in the last two decades, and most of them seem to work, at least in a subset of patients. However, since there is still a lack of treatment predictors, the treatment of obsessive-compulsive disorder (OCD) is still empirical and non-evidence based. Areas covered: In this paper, we review current and up-and-coming pharmacotherapy for OCD in adults, focusing on two emerging fields of research, inflammation and glutamate systems, since they have attracted the greatest attention in recent years in OCD pharmacological research. Expert opinion: Most of the investigated second-line agents seem to work at least in a subset of patients with OCD. These results raise an open question: what works for who? In our opinion, this question should be answered in a precision medicine perspective or, in other words, individualizing diagnostic processes and treatment approaches. In a precision medicine approach, OCD treatment should be sub-type specific, phase specific, multimodal and sequential, and, more importantly, dimensional.Keywords
Funding Information
- was not funded
This publication has 103 references indexed in Scilit:
- Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: Randomized double-blind placebo-controlled studyJournal of Affective Disorders, 2012
- Sarcosine Therapy for Obsessive Compulsive DisorderJournal of Clinical Psychopharmacology, 2011
- Obsessive–Compulsive Disorder Comorbidity: Clinical Assessment and Therapeutic ImplicationsFrontiers in Psychiatry, 2011
- Research Domain Criteria (RDoC): Toward a New Classification Framework for Research on Mental DisordersAmerican Journal of Psychiatry, 2010
- Carnosine protects against permanent cerebral ischemia in histidine decarboxylase knockout mice by reducing glutamate excitotoxicityFree Radical Biology and Medicine, 2010
- Neural concomitants of immunity—Focus on the vagus nerveNeuroImage, 2009
- Prevalence of mood and anxiety disorders in women with systemic lupus erythematosusArthritis Care & Research, 2009
- Obsessive–compulsive disorder: subclassification based on co-morbidityPsychological Medicine, 2008
- The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey ReplicationMolecular Psychiatry, 2008
- Cyclooxygenase-2 Inhibition Protects Cultured Cerebellar Granule Neurons from Glutamate-Mediated Cell DeathJournal of Neurotrauma, 2002